Poly-γ-glutamic acid nanoparticles as adjuvant and antigen carrier system for cancer vaccination

J Control Release. 2023 Oct:362:278-296. doi: 10.1016/j.jconrel.2023.08.049. Epub 2023 Sep 1.

Abstract

Vaccination is an innovative strategy for cancer treatment by leveraging various components of the patients' immunity to boost an anti-tumor immune response. Rationally designed nanoparticles are well suited to maximize cancer vaccination by the inclusion of immune stimulatory adjuvants. Also, nanoparticles might control the pharmacokinetics and destination of the immune potentiating compounds. Poly-γ-glutamic acid (γ-PGA) based nanoparticles (NPs), which have a natural origin, can be easily taken up by dendritic cells (DCs), which leads to the secretion of cytokines which ameliorates the stimulation capacity of T cells. The intrinsic adjuvant properties and antigen carrier properties of γ-PGA NPs have been the focus of recent investigations as they can modulate the tumor microenvironment, can contribute to systemic anti-tumor immunity and subsequently inhibit tumor growth. This review provides a comprehensive overview on the potential of γ-PGA NPs as antigen carriers and/or adjuvants for anti-cancer vaccination.

Keywords: Adjuvant; Cancer vaccines; Carrier system; Cellular immunity; γ-PGA nanoparticle.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Pharmaceutic
  • Antigens
  • Dendritic Cells
  • Glutamic Acid
  • Humans
  • Nanoparticles*
  • Neoplasms* / prevention & control
  • Polyglutamic Acid
  • Tumor Microenvironment
  • Vaccination

Substances

  • Glutamic Acid
  • poly(gamma-glutamic acid)
  • Adjuvants, Immunologic
  • Antigens
  • Adjuvants, Pharmaceutic
  • Polyglutamic Acid